Evidence method
Level · gp.fundamentals.debt_to_revenue
75.33% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
AKBA · Jun 30, 2025
Akebia Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-25-038600General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.20% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
35.77% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
43.13% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
26.74% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
84.12% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
22.55% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
17.63% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
4.28% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History12 statesHistory building
Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/9 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/9 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 81.12%
- Current
- 75.33%
- Delta
- -5.79%
- Previous
- 0.03%
- Current
- 0.20%
- Delta
- 0.17%
- Previous
- -23.70%
- Current
- 35.77%
- Delta
- 59.47%
- Previous
- 75.84%
- Current
- 43.13%
- Delta
- -32.71%
- Previous
- 34.41%
- Current
- 26.74%
- Delta
- -7.67%
- Previous
- 86.70%
- Current
- 84.12%
- Delta
- -2.58%
- Previous
- 23.57%
- Current
- 22.55%
- Delta
- -1.02%
- Previous
- 17.01%
- Current
- 17.63%
- Delta
- 0.62%
- Previous
- 3.81%
- Current
- 4.28%
- Delta
- 0.47%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · AKBA Fundamental State →Transitioned To · AKBA Fundamental State →Transitioned To · AKBA BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · AKBA CAPEX_INTENSITY_INCREASED →Transitioned To · AKBA CASH_GENERATION_INCREASED →Transitioned To · AKBA GROWTH_DECREASED →Transitioned To · AKBA INVENTORY_PRESSURE_DECREASED →Transitioned To · AKBA MARGIN_DECREASED →Transitioned To · AKBA PROFITABILITY_DECREASED →Transitioned To · AKBA R_AND_D_INTENSITY_INCREASED →Transitioned To · AKBA SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.